Why Atrium Therapeutics, Inc.’s (RNA) Stock Is Up 8.27%
As of Tuesday, October 20, Atrium Therapeutics, Inc.’s RNA share price has surged by 8.27%, which has investors questioning if this is right time to sell.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company’s development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy. It also focuses on pipeline to treat a range of genetic and cardiac diseases. It has a research collaboration and license agreement with Bristol-Myers Squibb Company and Eli Lilly and Company. The company was incorporated in 2025 and is headquartered in San Diego, California.
Commentary & Analysis
Why Atrium Therapeutics, Inc.’s (RNA) Stock Is Down 5.10%
As of Wednesday, September 23, Atrium Therapeutics, Inc.’s RNA share price has dipped by 5.10%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why Atrium Therapeutics, Inc.’s (RNA) Stock Is Down 6.04%
As of Wednesday, September 09, Atrium Therapeutics, Inc.’s RNA share price has dipped by 6.04%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why Atrium Therapeutics, Inc.’s (RNA) Stock Is Down 7.40%
As of Tuesday, September 08, Atrium Therapeutics, Inc.’s RNA share price has dipped by 7.40%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why Atrium Therapeutics, Inc.’s (RNA) Stock Is Down 20.93%
As of Tuesday, September 08, Atrium Therapeutics, Inc.’s RNA share price has dipped by 20.93%, which has investors questioning if this is right time to buy.Tudor Pop
Financial Summary
| Share Statistics | RNA | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $141.1 | $241.2 | 25% |
|
| Shares Out (Mil) | 17.1 | 53.4 | 28% |
|
| Institutional Ownership | 95.8% | 92.9% | 68% |
|
| Float (Mil) | 15.0 | 41.2 | 25% |
|
| Beta | na | 0.96 | na |
|
| Avg Daily Volume (000s) | 206 | 486 | 46% |
|
| Price Change (52-week) |
na | 48.4% | na |
|
| Growth | RNA | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 12.8% | na |
|
| Net Income (5yr) | na | (10.1%) | na |
|
| EPS (5yr) | na | 15.8% | na |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | na | (15.7%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 2 | 2 | 2 | |
| Current EPS | ($0.630) | ($3.865) | ($5.960) | |
| Month Ago EPS | ($0.670) | ($4.550) | ($8.060) | |
| # Rev Up | 0 | 0 | 0 | |
| # Rev Down | 0 | 1 | 1 | |
| Three Months Ago EPS | ($0.700) | ($3.590) | ($5.850) | |
| Year/Year Chg | (46.6%) | 21.1% | 69.5% | |
| Financials | RNA | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $36 | $37 | 17% |
|
| Net Income (TTM) (Mil) | ($66) | ($44) | 14% |
|
| EPS (TTM) | ($3.858) | ($1.600) | 9% |
|
| Operating Cash Flow (TTM) (Mil) | ($53) | ($33) | 9% |
|
| Net Cash Flow (TTM) (Mil) | $73 | $3 | 74% |
|
| Long-Term Debt (Q1) (Mil) | $0 | $4 | 0% |
|
| Enterprise Value (Q1) (Mil) | ($36) | $177 | 1% |
|
| Valuation | RNA | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.66 | 2.25 | 14% |
|
| P/E | na | 20.2 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | RNA | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | (56.4%) | 66.9% | 2% |
|
| Net Margin | (184.1%) | (73.7%) | 5% |
|
| ROA | (47.1%) | (47.3%) | 12% |
|
| ROE | (86.0%) | (53.3%) | 10% |
|
| Liabilities to Assets | 23.5% | 29.7% | 16% |
|
| F-Score | 1 | 2 | na |
|
Atrium Therapeutics, Inc. did not pass any screens on 10/29/2026.
